These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7820334)

  • 21. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers.
    Piñeyro-López A; Piñeyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez-Silva M; Waksman N; E Salazar-Leal M; Luján-Rangel R
    Clin Ther; 2007 Sep; 29(9):2049-54. PubMed ID: 18035203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence evaluation of two brands of metformin 500 mg tablets (Dialon & Glucophage)--in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2002 Oct; 23(7):301-6. PubMed ID: 12355581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects.
    Park JY; Kim KA; Kim SL; Park PW
    J Pharm Biomed Anal; 2004 Jun; 35(4):943-9. PubMed ID: 15193740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
    Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
    Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers.
    Najib NM; Idkaidek N; Adel A; Admour I; Astigarraga RE; De Nucci G; Alam SM; Dham R; Qumaruzaman
    Biopharm Drug Dispos; 2003 Oct; 24(7):315-20. PubMed ID: 14520685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur K; Singh I; Bade SR; Ashokraj Y
    Int J Pharm; 2006 Apr; 313(1-2):5-13. PubMed ID: 16517107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers.
    Hassan Y; Alfadly SO; Azmin MN; Peh KK; Tan TF; Noorizan AA; Ismail O
    Singapore Med J; 2007 Sep; 48(9):819-23. PubMed ID: 17728962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The multivariate assessment of bioequivalence.
    Chinchilli VM; Elswick RK
    J Biopharm Stat; 1997 Mar; 7(1):113-23. PubMed ID: 9056592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing individual bioequivalence with high-order cross-over designs: a unified procedure.
    Hsuan FC; Reeve R
    Stat Med; 2003 Sep; 22(18):2847-60. PubMed ID: 12953284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A group sequential approach to crossover trials for average bioequivalence.
    Hauck WW; Preston PE; Bois FY
    J Biopharm Stat; 1997 Mar; 7(1):87-96. PubMed ID: 9056590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of bioequivalence using a multiplicative model.
    Chow SC; Peace KE; Shao J
    J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing bioequivalence using genomic data.
    Chow SC; Shao J; Li L
    J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
    Lee JY; Kim BC; Park SG
    J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residuals and outliers in replicate design crossover studies.
    Schall R; Endrenyi L; Ring A
    J Biopharm Stat; 2010 Jul; 20(4):835-49. PubMed ID: 20496209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.